Michael Atkins

Dr. Michael Atkins, a leading authority in metastatic melanoma and first author of the pioneering DREAMseq trial, delves into cutting-edge treatment options. He shares an inspiring case of an elderly patient and how immunotherapy can lead to rapid tumor regression. Discussion includes the impact of advanced therapies like BRAF-MEK inhibitors and the new Relatlimab-Nivolumab combination. Insights on treating brain metastases emphasize the need for teamwork in decision-making. Atkins also covers strategies for various melanoma subtypes and offers advice for budding oncologists.

Dr. Michael Atkins, a renowned expert and deputy director of the Georgetown Lombardi Comprehensive Cancer Center, discusses the latest in localized melanoma treatment. Breakthroughs in immunotherapy and targeted therapies are highlighted, showcasing improved survival rates. He dives into the critical staging process, emphasizing tumor thickness and lymph node involvement. The conversation also covers the effectiveness of neoadjuvant therapies like Pembrolizumab and the potential of oncolytic viruses in melanoma treatment, offering a glimpse into future clinical trials.

Dr. Michael Atkins and Dr. Vernon Sondak discuss the updated systemic therapy for melanoma recommendations, including neoadjuvant and adjuvant therapy for resected cutaneous melanoma, options for unresectable/metastatic melanoma, and therapies for non-cutaneous melanoma. They highlight the importance of the guideline and address pressing questions for better treatment strategies.